Dicerna Announces Dosing of First Patient in Phase 1 Clinical Trial of DCR-HBVS for the Treatment of Chronic Hepatitis B Virus

Dicerna Pharmaceuticals announced the dosing of the first patient in its Phase 1 clinical trial of DCR-HBVS, the Company’s investigational GalXCTM-based therapy for the treatment of chronic hepatitis B virus (HBV) infection in adults. The Company anticipates human proof-of-concept data from the Phase 1 trial, which is known as DCR-HBVS-101, in the fourth quarter of 2019. In January...

Promethera Biosciences Announces First-Dosing in Phase 2a Clinical Study Evaluating World’s First Liver Stem Cell Therapy in Late-Stage NASH Patients

PANASH Trial will Evaluate Safety and Early Signs of Efficacy of HepaStem® in F3- F4-grade NASH Patients Promethera Biosciences SA, a global innovator in cell-based medicines and liver diseases, announced the dosing of a first patient in a Phase 2a clinical study for the company’s HepaStem development program in patients with  late stage non-alcoholic steatohepatitis (NASH). The multicenter,...

Arrowhead Pharmaceuticals reports advances in genetic therapies for liver disease and Hepatitis B

Arrowhead Pharmaceuticals has released a flurry of press releases related to their genetic therapy approaches. Here is a quick summary of what we have seen. Arrowhead's ARO-HBV, a third generation RNA interference therapy for Hepatitis B, presented promising results at the 2019 International Liver Congress in a Phase 1/2 clinical study. The therapy was shown to rapidly...

Promethera Biosciences presents positive phase 2a results from stem cell based liver failure treatment

Promethera Biosciences put out a press release today highlighting the phase 2a results for their stem cell based liver therapy, HepaStem. The treatment targets 'Acute-on-Chronic Liver Failure (ACLF) or acute decompensation (AD) at high risk of developing ACLF', and aims to provide an alternative to liver transplantation by salvaging livers that are in the process of failing.